Irak4 degraders and uses thereof

Patent metadata

Field	Value
Publication number	US-2025082645-A1
Application number	US-202418955054-A
Country	US
Kind code	A1
Filing date	Nov 21, 2024
Priority date	Feb 15, 2021
Publication date	Mar 13, 2025
Grant date	—

Abstract

The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.

First claim

1 . A spray-dried formulation comprising Compound A or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer;
wherein Compound A is 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(difluoromethyl)-1-((1r,4R)-4-((4-((3-(1-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidin-1-yl)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.

2 . The spray-dried formulation of claim 1 , comprising Compound A free base.

3 . The spray-dried formulation of claim 1 , comprising Compound A HCl.

4 . The spray-dried formulation of any one of claims 1-3 , wherein the pharmaceutically acceptable polymer is selected from PVP-VA, HPMC, HPMCP-55, HPMCAS-M, TPGS, HPMCAS-L, and MCC.

5 . The spray-dried formulation of any one of claims 1-4 , comprising about 20-40% wt/wt Compound A, or a pharmaceutically acceptable salt thereof.

6 . The spray-dried formulation of any one of claims 1-5 , comprising about 60-80% wt/wt of pharmaceutically acceptable polymer.

7 . The spray-dried formulation of any one of claims 1-6 , comprising 25:75 (% wt/wt) Compound A free base:HPMCAS-M.

8 . A unit dosage form comprising the spray-dried formulation of any one of claims 1-7 .

9 . The unit dosage form of claim 8 , wherein the spray-dried formulation is about 45-55% wt/wt of the unit dosage form.

10 . The unit dosage form of claim 8 or 9 , further comprising a filler, wherein the filler is selected from mannitol, microcrystalline cellulose, or mixtures thereof.

11 . The unit dosage form of any one of claims 8-10 , further comprising a glidant, wherein the glidant is colloidal silicon dioxide.

12 . The unit dosage form of any one of claims 8-11 , further comprising a disintegrant, wherein the disintegrant is croscarmellose sodium.

13 . The unit dosage form of any one of claims 8-12 , further comprising a solubility enhancer, wherein the solubility enhancer is hydroxypropyl-beta-cyclodextrin (HPβCD).

14 . The unit dosage form of any one of claims 8-13 , further comprising a lubricant, wherein the lubricant is stearyl fumarate sodium.

15 . The unit dosage form of any one of claims 8-14 , comprising about 10-500 mg of Compound A or a pharmaceutically acceptable salt thereof.

16 . The unit dosage form of any one of claims 8-15 , comprising about 25 mg or about 100 mg of Compound A or a pharmaceutically acceptable salt thereof.

17 . The unit dosage form of any one of claims 8-16 , which is a tablet of about 208 mg, comprising:
i) a tablet core of about 200 mg, comprising
intragranularly: about 25 mg Compound A free base, about 75 mg HPMCAS-M, about 15 mg mannitol, about 15 mg microcrystalline cellulose, about 40 mg hydroxypropyl-beta-cyclodextrin, about 19.34 mg croscarmellose sodium, about 2 mg stearyl fumarate sodium, and about 2 mg colloidal silicon dioxide; and
extragranularly: about 4.66 mg croscarmellose sodium, about 1 mg stearyl fumarate sodium, and about 1 mg colloidal silicon dioxide; and
ii) Opadry® II Yellow Film Coating of about 8 mg, comprising about 3.2 mg Polyvinyl Alcohol, 1.616 mg Macrogol/PEG, 1.872 mg Titanium Dioxide, 0.128 mg Iron Oxide, and 1.184 mg Talc.

18 . The unit dosage form of any one of claims 8-16 , which is a tablet of about 824 mg, comprising:
i) a tablet core of about 800 mg, comprising
intragranularly: about 100 mg Compound A free base, about 300 mg HPMCAS-M, about 45 mg mannitol, about 45 mg microcrystalline cellulose, about 160 mg hydroxypropyl-beta-cyclodextrin, about 77.36 mg croscarmellose sodium, about 8 mg stearyl fumarate sodium, and about 8 mg colloidal silicon dioxide; and
extragranularly: about 18.64 mg croscarmellose sodium, about 4 mg stearyl fumarate sodium, and about 4 mg colloidal silicon dioxide; and
ii) Opadry® II Yellow Film Coating of about 24 mg, comprising about 9.6 mg Polyvinyl Alcohol, 4.848 mg Macrogol/PEG, 5.616 mg Titanium Dioxide, 0.384 mg Iron Oxide, and 3.552 mg Talc.

19 . A method for treating an autoimmune/autoinflammatory disease or a hematological malignancy in a patient, comprising administering to the patient a therapeutically effect amount of the spray-dried formulation of any one of claims 1-7 , or the unit dosage form of any one of claims 8-18 .

20 . The method of claim 19 , wherein the autoimmune/autoinflammatory disease is selected from a cutaneous, rheumatic, and gastrointestinal autoimmune/autoinflammatory disease.

21 . The method of claim 20 , wherein the autoimmune/autoinflammatory disease is a cutaneous autoimmune/autoinflammatory disease selected from atopic dermatitis (AD) and hidradenitis suppurativa (HS).

22 . The method of any one of claim 18-21 , wherein the method comprises administering up to about 1600 mg of Compound A or a pharmaceutically acceptable salt thereof to the patient.

23 . The method of any one of claims 19-22 , wherein the method comprises administering up to about 1400 mg of Compound A or a pharmaceutically acceptable salt thereof to the patient.

24 . The method of any one of claims 19-23 , wherein the method comprises administering about 25-1400 mg (for example, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 500 mg, about 1000 mg, or about 1400 mg) of compound A or a pharmaceutically acceptable salt thereof to the patient per day.

25 . The method of any one of claims 19-23 , wherein the method comprises daily administering up to 100 mg, up to 150 mg, or up to 200 mg of Compound A, or a pharmaceutically acceptable salt thereof.

Assignees

• Kymera Therapeutics Inc

Inventors

• Gollob Jared
• Davis Jeffrey
• Mcdonald Alice
• Rong Haojing

Classifications

• A61K9/205

  Polysaccharides, e.g. alginate, gums; Cyclodextrin · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/2853

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide) · CPC title

• A61K9/2027

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• A61K9/2013

  Organic compounds, e.g. phospholipids, fats · CPC title